This #RareDiseaseDay is special, as we’ve teamed up with renowned jewelry designer, Jennifer Fisher, to help raise awareness of desmoid tumors. We’re inspired by patients who are overcoming their desmoid tumor. Visit DesmoidTumors.com to learn more. For US audiences only.

Marketing & Pharma featured our collaboration with Jennifer Fisher and her experience living with desmoid tumors which highlights the need for patients to act before their desmoid tumor takes over. Read the full article: marketingandpharma.com/springworks-an…

SpringWorks is proud to be a sponsor of the British Sarcoma Group Annual Conference in Newcastle, UK. We look forward to making the most of the educational and networking opportunities with British Sarcoma Group. #BSGConference2025 #Sarcoma

Watch this episode from Progress, Potential, And Possibilities, featuring sarcoma specialist, Dr. Alessandra Maleddu. She discusses the unique challenges of diagnosing and treating rare, locally aggressive #DesmoidTumors. youtube.com/watch?v=7EMjsO…

We are proud that #SpringWorkers are passionate about what they do and work with urgency on behalf of patients with devastating rare diseases. This #EmployeeAppreciationDay, we asked our Chief People Officer, Daniel Pichl, what he admires most about the SpringWorks team.

In recognition of International Women’s Day, our Women+ Initiative Network employee resource group will host a panel discussion with the HBA’s RTP Chapter. The panelists share what it means to #AccelerateAction for women's advancement. #IWD2025

We are excited to be at the German Sarcoma Conference. Attendees can visit our booth to learn more about our company and who we are. #SarcomaCare

Jennifer Fisher, #DesmoidTumor patient advocate, joined Rosanna Scotto of FOX 5 NY this morning to share her journey living with a desmoid tumor and to highlight available treatments, including non-surgical treatment options. Hear her story: desmoidtumors.com

Bringing the first FDA-approved therapy to patients with #DesmoidTumors was a story of tenacity, persistence and collaboration. SpringWorks is honored to be serving the desmoid tumor community and is grateful to our collaborators that helped make this milestone happen.

Desmoid tumors are rare, aggressive, soft tissue tumors that can have a profound impact on an individual’s life. Jennifer Fisher, jewelry designer and patient advocate, shares her journey, the importance of taking action and speaking with a specialist: desmoidtumors.com/support-resour…

We are proud to sponsor the ESMO - Eur. Oncology Sarcoma and Rare Cancers Congress in Lugano, Switzerland. We look forward to meeting with others who are committed to advancing care and improving outcomes for patients with sarcomas and rare cancers. #ESMORareCancers25

We're pleased to share that data from our Phase 2b trial in children and adults with neurofibromatosis type 1 with plexiform neurofibromas (#NF1-PN) will be presented at the American Academy of Neurology Annual Meeting. See you there! #AANAM

We are pleased to have received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for our MEK inhibitor for the treatment of adults and children with NF1-PN. Read more: ir.springworkstx.com/news-releases/…

We are excited to be at the 2025 ASCO Meeting in Chicago. If you’re at #ASCO25, stop by our booth (# 23165) to learn more about how we are delivering on our commitment to patients living with rare and devastating diseases.

Great to share our updated ReNeu data at the 2025 NF Conference. Thank you to Children's Tumor Fdn for bringing together medical experts across disciplines, patients and caregivers. Together, we can keep transforming outcomes for people with NF. #NFCon2025 #EndNF

As of today, SpringWorks Therapeutics is officially a Healthcare company of Merck KGaA, Darmstadt, Germany. Together, we remain focused on helping patients with rare tumors live longer, better lives. Learn more: emdgroup.com/en/news/spring…

We are excited to share that the European Commission has granted conditional approval for our MEK inhibitor for the treatment of adult and pediatric patients with #NF1-PN. Read more: springworkstx.gcs-web.com/news-releases/…

#NF1 is a genetic disorder that affects both children and adults. Patients with NF1 have approximately a 30-50% lifetime risk of developing plexiform neurofibromas, or PNs, which are tumors that grow along nerves. Learn more:  nf1pn.com

We are honored to be named a #PrixGalien USA nominee for “Best Product for Rare/Orphan Diseases” for our treatment for adults with #DesmoidTumors. We look forward to attending the awards ceremony in October.

The European Commission approved our gamma secretase inhibitor for the treatment of adults with progressing desmoid tumors who require systemic treatment. Until now, desmoid tumor patients in Europe had no approved treatment options. bit.ly/4fDdzAK #AsOneforPatients